Catherine Coleman
#179,947
Most Influential Person Now
Catherine Coleman's AcademicInfluence.com Rankings
Catherine Colemancomputer-science Degrees
Computer Science
#11333
World Rank
#11998
Historical Rank
Informatics
#72
World Rank
#76
Historical Rank

Catherine Colemanphilosophy Degrees
Philosophy
#11236
World Rank
#15445
Historical Rank
Logic
#8045
World Rank
#10009
Historical Rank

Download Badge
Computer Science Philosophy
Catherine Coleman's Degrees
- Doctorate Medicine Stanford University
Why Is Catherine Coleman Influential?
(Suggest an Edit or Addition)Catherine Coleman's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. (1999) (381)
- Analysis of prostate and seminal vesicle motion: implications for treatment planning. (1996) (273)
- Hypoxia in tumors: a paradigm for the approach to biochemical and physiologic heterogeneity. (1988) (258)
- Improved methodology for analyzing local and distant recurrence. (1990) (221)
- Real-time magnetic resonance image-guided interstitial brachytherapy in the treatment of select patients with clinically localized prostate cancer. (1998) (207)
- Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. (1988) (166)
- Radioimmunotherapy with alpha-particle-emitting immunoconjugates. (1988) (161)
- Rationale for use of local hyperthermia with radiation therapy and selected anticancer drugs in locally advanced human malignancies. (1988) (155)
- Stereotactic radiosurgery for intracranial arteriovenous malformations using a standard linear accelerator. (1989) (155)
- Results of stereotactic brachytherapy used in the initial management of patients with glioblastoma. (1990) (137)
- Chemical modifiers of cancer treatment. (1988) (129)
- Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. (1986) (129)
- Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). (1986) (122)
- Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml. (1997) (110)
- Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy (1994) (104)
- Workshop on partial breast irradiation: state of the art and the science, Bethesda, MD, December 8-10, 2002. (2004) (96)
- Analysis of prostate and seminal vesicle motion (1993) (92)
- Modulation of radiation-induced apoptosis and G2/M block in murine T-lymphoma cells. (1995) (88)
- Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508. (1984) (86)
- Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out. (1996) (79)
- 5 year biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer (1998) (78)
- Clinical radiosensitization: why it does and does not work. (1999) (71)
- Radiation and chemotherapy sensitizers and protectors. (1990) (65)
- Minimal long-term cardiopulmonary dysfunction following treatment for Hodgkin's disease. (1987) (64)
- Secondary neoplasms in patients treated for cancer: etiology and perspective. (1982) (63)
- Hypoxic cell radiosensitizers: expectations and progress in drug development. (1985) (61)
- Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile. (1987) (61)
- Phase I trial of the hypoxic cell radiosensitizer SR-2508: the results of the five to six week drug schedule. (1986) (60)
- The use of probenecid as a chemoprotector against cisplatin nephrotoxicity (1991) (55)
- A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma. (2003) (55)
- Modifiers of radiation-induced apoptosis. (1993) (52)
- Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation. (1994) (50)
- Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma. (1992) (49)
- Alpha particle radio-immunotherapy: animal models and clinical prospects. (1989) (49)
- Biologic basis for radiation oncology. (1996) (48)
- Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid. (1984) (46)
- Clinical trials with hypoxic cell sensitizers: time to retrench or time to push forward? (1984) (42)
- Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03. (1990) (41)
- Secondary malignancy after treatment of Hodgkin's disease: an evolving picture. (1986) (39)
- Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors. (1999) (38)
- Apoptosis and clonogenic cell death in PC3 human prostate cancer cells after treatment with gamma radiation and suramin. (1997) (37)
- Interaction of SR-4233 with hyperthermia and radiation in the FSaIIC murine fibrosarcoma tumor system in vitro and in vivo. (1990) (36)
- Initial pharmacology and toxicology of intravenous desmethylmisonidazole. (1982) (30)
- Sensitizers and protectors of radiation and chemotherapy. (2001) (30)
- Signal transduction inhibitors as modifiers of radiation therapy in human prostate carcinoma xenografts (1996) (29)
- Splenic injury caused by therapeutic irradiation (1981) (28)
- Interaction of tomudex with radiation in vitro and in vivo. (1998) (24)
- Radiation-induced apoptosis in F9 teratocarcinoma cells. (1994) (24)
- Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV. (1997) (22)
- Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma. (1998) (22)
- The efficacy of pharmacokinetic monitoring and dose modification of etanidazole on the incidence of neurotoxicity: results from a phase II trial of etanidazole and radiation therapy in locally advanced prostate cancer. (1992) (21)
- Rate of relapse following treatment for localized prostate cancer: a critical analysis of retrospective reports. (1994) (21)
- Effect of cell cycle stage, dose rate and repair of sublethal damage on radiation-induced apoptosis in F9 teratocarcinoma cells. (1995) (21)
- Protection against SR 4233 (Tirapazamine) aerobic cytotoxicity by the metal chelators desferrioxamine and tiron. (1994) (20)
- Initial results of a phase I trial of continuous infusion SR 2508 (etanidazole): a radiation therapy oncology group study. (1989) (20)
- Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma. (1991) (19)
- Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG Protocol 90-20). (1996) (19)
- Enhancement of the clinical activity of melphalan by the hypoxic cell sensitizer misonidazole. (1988) (18)
- Training the radiation oncologist for the twenty-first century. (1996) (18)
- Beneficial liaisons: radiobiology meets cellular and molecular biology (1993) (18)
- Phase I trial of intravenous L-phenylalanine mustard plus the sensitizer misonidazole. (1983) (17)
- Novel concepts in modification of radiation sensitivity. (1994) (17)
- Pharmacokinetic monitoring and dose modification of etanidazole in the RTOG 85-27 phase III head and neck trial. (1997) (16)
- Effects of nitroimidazoles on neuronal cells in vitro. (1989) (16)
- Modulating the Radiation Response (1996) (15)
- SR-4233 (Tirapazamine) acts as an uncoupler of oxidative phosphorylation in human MCF-7 breast carcinoma cells. (1994) (15)
- RTOG #89-06: a phase I study to evaluate intraoperative radiation therapy and the hypoxic cell sensitizer etanidazole in locally advanced malignancies. (1994) (15)
- Bioreductive metabolism of SR-4233 (WIN 59075) by whole cell suspensions under aerobic and hypoxic conditions: role of the pentose cycle and implications for the mechanism of cytotoxicity observed in air. (1994) (15)
- Final report of the phase I trial of continuous infusion etanidazole (SR 2508): a Radiation Therapy Oncology Group study. (1992) (15)
- Beneficial liaisons: radiobiology meets cellular and molecular biology. (1993) (14)
- A phase I study of etanidazole and radiotherapy in malignant glioma. (1994) (13)
- Molecular biology in radiation oncology. Radiation oncology perspective of BRCA1 and BRCA2. (1999) (13)
- Distribution of etanidzole into human brain tumors: Implications for treating high grade gliomas (1992) (12)
- New directions in brachytherapy. (2002) (11)
- Prostate cancer. Technology versus biology (1993) (10)
- Chemical sensitizers and protectors. (1998) (10)
- Of what use is molecular biology to the practicing radiation oncologist? (1998) (10)
- Current scientific issues related to clinical radiation oncology. (1998) (10)
- Results of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (1984) (10)
- Pharmacodynamics of prolonged treatment with L,S-buthionine sulfoximine. (1994) (10)
- Modification of the aerobic cytotoxicity of etanidazole. (1994) (10)
- Phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer. (1994) (9)
- Estimating the risk of second primary tumors following cancer treatment. (1989) (9)
- Elevation of mouse kidney thiol content following administration of glutathione. (1992) (9)
- The development of an oral prodrug, SR-2545, of the 2-nitroimidazole radiosensitizer SR-2508. (1982) (9)
- Phase III study of ibuprofen versus placebo for radiation-induced genitourinary side effects. (2002) (9)
- The challenge for conformal therapy for prostate cancer. (1993) (9)
- Role of additional radiotherapy in advanced stages of Hodgkin's disease. (1992) (8)
- Chemoradiation and adjuvant chemotherapy for glioblastoma: why does so much therapy yield so little improvement in survival? (1995) (8)
- Lisofylline as a modifier of radiation therapy. (1996) (8)
- Tumor oxygenation after hyperthermia in the rat 13762 mammary carcinoma and the DU-145 human prostate carcinoma. (1997) (8)
- The effect of vitamin B6 on the neurotoxicity and pharmacology of desmethylmisonidazole and misonidazole: clinical and laboratory studies. (1984) (7)
- Combined Modality Therapy Using Cytotoxic Agents and Radiation Therapy (1988) (7)
- Combined-modality therapy of esophageal cancer with radiotherapy, etanidazole, and cisplatin-fluorouracil, with or without surgery: neurotoxicity, other toxicities and outcome. (1994) (6)
- Effect of OH scavenging on the yield of radiation-induced DNA double-strand breaks in isolated nuclei. (1988) (6)
- COMMENTARY Workshop on Partial Breast Irradiation: State of the Art and the Science, Bethesda, MD, (2004) (6)
- The current status of drug development of hypoxic cell radiosensitizers and their potential role in gynecologic oncology. (1984) (5)
- Inflammatory breast issue. (2003) (5)
- Conference summary: the ninth international conference on the Chemical Modifiers of Cancer Treatment. (1996) (5)
- Phase I pharmacokinetic study of the hypoxic cell sensitizer etanidazole with carboplatin and cyclophosphamide in the treatment of advanced ovarian cancer. (1994) (4)
- Metabolic effects of antibodies on platelets. (1973) (4)
- Pilot study of local hyperthermia, radiation therapy, etanidazole, and cisplatin for advanced superficial tumours. (1995) (4)
- Final report: Phase I trial of desmethylmisonidazole (DMM) - an hypoxic cell sensitizer (1982) (4)
- Logistics in designing clinical trials for etanidazole (SR 2508): an RTOG experience. (1992) (4)
- Advances in cellular and molecular radiation oncology. (1996) (4)
- Alternative and future strategies in the treatment of malignant gliomas (1991) (3)
- Analyzing local and distant recurrence (Reply) (1990) (3)
- The hall-mark of modern radiation oncology. (1994) (3)
- Reversal of drug-resistance by exposure of mcf-7 or mcf-7 cddp human breast-carcinoma cells to sr-4233 or etanidazole under hypoxic conditions. (1993) (3)
- We're from the Government and We're Here to Help You (1994) (3)
- Research in medical physics. (2001) (3)
- Neuropathy of desmethylmisonidazole (DMM): Clinical and pathological description (1982) (3)
- Distribution of etanidazole into human brain tumors: implications for treating high grade gliomas. (1992) (3)
- Can irradiation of lewis lung carcinoma primary tumor cause the growth of lung metastases (1998) (3)
- CT of irradiated solid tumor metastases to the brain (1982) (3)
- Mentors, mensches, and models. (2009) (3)
- Lymphoblastic lymphoma. (1990) (3)
- "Reports of my death [may be] greatly exaggerated" (adapted from Mark Twain)--in response to Dr. J. M. Brown, IJROBP 32:883-885; 1995. (1995) (3)
- Keynote address: Biochemical modification of therapeutic response (1992) (2)
- CLINICAL TRIALS OF ETANIDAZOLE (SR 2508): RTOG AND JOINT CENTER FOR RADIATION THERAPY TRIALS (1992) (2)
- 2023 Survival results of a phase I study of etanidazole and radiotherapy in patients with malignant glioma (1996) (2)
- Carcinoma of the prostate: praising Stanford's accomplishments. (1994) (2)
- Use of the hypoxic cell sensitizer etanidazole (SR-2508) with intravenous melphalan and prednisone in the treatment of multiple myeloma: a pharmacokinetic study. (1994) (2)
- Modification of radiotherapy by radiosensitizers and cancer chemotherapy agents. I. Radiosensitizers. (1989) (2)
- Transitioning to Environmentally Sustainable, Climate-Smart Radiation Oncology Care. (2022) (2)
- Re: The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. (1994) (2)
- A phase I pilot study to evaluate intraoperative radiation therapy (IORT) and the hypoxic cell sensitizer etanidazole (ETA) in patients with locally advanced malignancies (RTOG protocol 89-06) (1992) (2)
- Hypoxic cell sensitizers: Theoretical approaches and clinical strategies (1990) (1)
- Technology-enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers (TEACH) (2020) (1)
- Phase I trial of desmethylmisonioazole — A new hypoxic cell sensitizer (1981) (1)
- Pharmacology and toxicology of desmethylmisonidazole (DMM) - An hypoxic cell sensitizer (1982) (1)
- S17 05 TA – CLINICAL TRIALS WITH ETANIDAZOLE (SR 2508) (1991) (1)
- 1002 Equivalent 5 year bNED in select prostate cancer patients managed with surgery or radiation therapy despit exclusion of the seminal vesicles from the clinical target volume (1997) (1)
- Investing in our future: listening to those who will take us where we need to go. (2001) (1)
- Hypoxic Cell Sensitizers (1991) (1)
- Current role of nitroimidazole sensitizers and sulfhydryl protectors in clinical oncology (1982) (0)
- Chemical modifiers of radiation and chemotherapy: tumor sensitization and normal tissue protection (1984) (0)
- Progress in systemic radiotherapy. Authors' reply (2005) (0)
- 201C Molecular biology — Part II: Beneficial liaisons: Radiobiology meets cellular and molecular biology (1996) (0)
- 62 ASTRO fellowship project: Heat shock proteins and apoptosis in prostate adenocarcinoma (1996) (0)
- THERMOCHEMORADIOTHERAPY IN VIVO (1991) (0)
- Are radiation oncologists serious about systemic radiation therapy and if not, should we be? (2004) (0)
- Biochemical modification of therapeutic response. (1992) (0)
- NAPRT1 and p53 Status in Cancer and Normal Cells Modulate Induction of ROS Induced by GMX1777/1778: Implication for Synthetic Lethality in Tumors Defective in NAPRT1 and p53 (2010) (0)
- CHAPTER 12 CYTOGENETIC BIODOSIMETRY (2012) (0)
- ASTRO refresher course descriptionHypoxic cell sensitizers: Theoretical approaches and clinical strategie (1990) (0)
- 18 Novel radiation modifiers (1995) (0)
- The Harvard Joint Center for Radiation Therapy, 1968-1999: a unique concept and its relationship to the prevailing times in academic medicine. (2000) (0)
- 183Of what use is molecular and cellular biology to the practicing radiation oncologist (1996) (0)
- In response to Dr. Order (2005) (0)
- Urologic oncology: extraordinary opportunities for discovery (2001) (0)
- Effect of BSO and etanidazole on neurofilament degradation in neonatal rat spinal cord cultures. (1996) (0)
- Inhibition of c/s-Diamminedichloroplatinum Secretion by the Human Kidney with Probenecid1 (2006) (0)
- Career Options in Radiation Oncology (2021) (0)
- Sensitization of Chinese hamster ovary cells to melphalan by etanidazole under intermittent hypoxia. (1992) (0)
- 39 Normal tissue countermeasures (2006) (0)
- In response to Drs. Schulz and Kagan (2002) (0)
- The effect of postoperative (POSTOP) and primary radiation therapy (RT) on delivered dose of adjuvant cytoxan, methotrexate, 5-FU (CMF) chemotherapy (CT) in breast cancer (1982) (0)
- Protection against SR 4233 aerobic cytotoxicity by the metal chelators desferrioxamine and tiron (1993) (0)
- Therapeutic implications of prolonged treatment with L,S,-Buthione sulfoximine (1992) (0)
- 7 Hypoxic Cell Sensitizers (1991) (0)
- Pretreatment N omogram f or P rostate-Specifi c A ntigen Recurrence A fter R adical P rostatectomy o r E xternal-Beam Radiation T herapy f or C linically L ocalized P rostate C ancer (1999) (0)
- Modulation of Radiation-Induced Apoptosis (2021) (0)
This paper list is powered by the following services: